AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a f…
$5.97-6.13%
报价 2026-11-16
市值
$294M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -66.5%
$5.97$17.82
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AGMBAgomAb Therapeutics N.V. American Depositary Shares | $294M | -6.1% | – | 0% | – | – | – | |
| KYTXKyverna Therapeutics, Inc. | $300.9M | -5.7% | +86.6% | 0% | – | – | – | |
| BNTCBenitec Biopharma Inc. | $298M | -5.5% | -13.8% | 0% | – | – | – | |
| IPSCCentury Therapeutics, Inc. | $297.8M | -0.6% | -95.7% | 0% | – | – | – | |
| MPLTMapLight Therapeutics, Inc. | $294.1M | -4.8% | – | – | – | – | – | |
| EVMNFunctional Brands, Inc. Common Stock | $293.6M | -6.9% | -96.2% | 100% | – | – | – | |
| PEPGPepGen Inc. | $290.2M | -3.9% | +837.5% | 0% | – | – | – | |
| XFORX4 Pharmaceuticals, Inc. | $289M | -9.3% | -49.4% | 81.2% | – | – | – | |
| EDITEditas Medicine, Inc. | $288.6M | -13.8% | +27.8% | 56.9% | – | – | – | |
| 同行中位数 | – | – | -13.8% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 EUR(非美元)暂无季度数据(首次研究运行后填充)。
研究材料
Filing 摘要
暂无 filing 摘要。
电话会纪要摘要
暂无纪要摘要。